tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Regenxbio price target lowered to $12 from $14 at Goldman Sachs
PremiumThe FlyRegenxbio price target lowered to $12 from $14 at Goldman Sachs
14d ago
Closing Bell Movers: Upwork down over 20% on soft guidance
Premium
The Fly
Closing Bell Movers: Upwork down over 20% on soft guidance
14d ago
Regenxbio price target lowered to $45 from $50 at Clear Street
Premium
The Fly
Regenxbio price target lowered to $45 from $50 at Clear Street
15d ago
RegenXBio: Clinical Hold on RGX-111/121 Seen as Manageable Timing Issue, Core Gene Therapy Platform and Key Value Drivers Remain Intact Supporting Buy Rating
PremiumRatingsRegenXBio: Clinical Hold on RGX-111/121 Seen as Manageable Timing Issue, Core Gene Therapy Platform and Key Value Drivers Remain Intact Supporting Buy Rating
27d ago
Stifel says Regenxbio’s RGX-121 delay not unexpected, not difficult to resolve
Premium
The Fly
Stifel says Regenxbio’s RGX-121 delay not unexpected, not difficult to resolve
27d ago
Midday Fly By: AT&T reports Q4 beat, Amazon cuts 16,000 jobs
Premium
The Fly
Midday Fly By: AT&T reports Q4 beat, Amazon cuts 16,000 jobs
27d ago
Regenxbio down 35% to $8.59 after FDA places clinical hold on RGX-111
PremiumThe FlyRegenxbio down 35% to $8.59 after FDA places clinical hold on RGX-111
27d ago
Regenxbio announces FDA places clinical hold of RGX-111
Premium
The Fly
Regenxbio announces FDA places clinical hold of RGX-111
27d ago
Regenxbio assumed with an Overweight at Barclays
Premium
The Fly
Regenxbio assumed with an Overweight at Barclays
28d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100